Skip to main content
Lunai Bioworks Inc. logo

Lunai Bioworks Inc. — Investor Relations & Filings

Ticker · RENB ISIN · US29350E1047 US Professional, scientific and technical activities
Open in API
Filings indexed 580 across all filing types
Latest filing 2024-01-16 Regulatory Filings
Country US United States of America
Listing US RENB

About Lunai Bioworks Inc.

https://www.lunaibio.com

Lunai Bioworks Inc. is a pre-clinical stage biotechnology company that utilizes artificial intelligence for drug discovery and biodefense. The company focuses on pioneering safe and responsible generative biology to develop new therapies. By harnessing phenomics and AI, it aims to decode disease signals and translate them into treatments. Its proprietary Transformer Platform is designed to accelerate drug discovery processes. Lunai Bioworks develops medicines, diagnostics, and biodefense products, with a pipeline that includes programs for neurodegenerative conditions like Alzheimer's disease.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 16, 2024. It announces the publication of a shareholder letter and an investor presentation available on the company's website. The document itself is short (3800 characters) and primarily serves as a notification of these materials being furnished as exhibits. There are no detailed financial statements or substantive financial data within this text. According to the 'Menu vs Meal' rule, this is an announcement of report availability rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous filings and announcements that do not fit other categories.
2024-01-16 English
FORM DEFA14A
Remuneration Information Classification · 95% confidence The document is titled 'FORM DEFA14A' and is identified as a 'Supplement to Proxy Statement' for a special meeting of stockholders. It references the Securities Exchange Act of 1934 and Schedule 14A, which are related to proxy statements and shareholder voting materials. The content includes detailed information about the company's business combination, CEO message, and plans related to the proxy statement. There is no indication that this is the proxy statement itself but rather additional materials supplementing it. The document is not an annual report, earnings release, or any other financial report. It is clearly related to proxy solicitation and shareholder voting information. Therefore, the appropriate classification is 'Remuneration Information (DEF 14A)' as the form DEFA14A is a definitive additional proxy solicitation material filing under SEC rules, which falls under the Remuneration Information category in this context.
2024-01-16 English
DEFM14A Filing
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, as indicated by the header and the title 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' It is a definitive proxy statement for a special meeting of stockholders of Renovaro Biosciences Inc. The content includes detailed descriptions of proposals to be voted on by shareholders, including approval of stock issuance, amendments to the certificate of incorporation, stock option repricing, and equity incentive plan amendments. It also contains background information on the transaction, risk factors, management discussion and analysis, and annexes with agreements and proposed amendments. The document is clearly a proxy solicitation and information statement intended to provide shareholders with information necessary to make informed voting decisions at the special meeting. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and detailed content confirm it is the full proxy statement, not just an announcement or summary.
2024-01-03 English
PREM14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'PREM14A' and is identified as a 'Schedule 14A Proxy Statement' filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is a proxy statement related to a special meeting of stockholders of Renovaro Biosciences Inc. The content includes detailed information about the special meeting, proposals to be voted on by shareholders, background and reasons for a transaction (acquisition of GEDi Cube Intl Ltd.), amendments to the certificate of incorporation, stock issuance, and equity incentive plans. The document also contains sections typical of proxy statements such as risk factors, voting procedures, and detailed descriptions of proposals. The presence of the term 'proxy statement' and the detailed solicitation of shareholder votes for corporate actions clearly identifies this as a Proxy Solicitation & Information Statement filing. The document is not an announcement or a brief summary but a full proxy statement with comprehensive information for shareholders to make informed voting decisions.
2023-12-22 English
FORM DEFA14A
Remuneration Information Classification · 95% confidence The document is titled 'FORM DEFA14A' and references 'Schedule 14A' and 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' It is marked as 'Definitive Additional Materials' related to a proxy statement for Renovaro Biosciences Inc. The content includes a transcript of an interview with the CEO, which is part of the additional materials filed with the proxy statement. The presence of 'DEFA14A' and the proxy statement context clearly indicates this is a filing related to executive compensation or governance matters typically associated with proxy materials. The document is not a full annual report, earnings release, or other financial report but rather additional materials to a proxy statement, which aligns with Remuneration Information filings under the DEF 14A form category. Therefore, the correct classification is 'DEF 14A' with high confidence.
2023-12-22 English
FORM DEFA14A
Remuneration Information Classification · 100% confidence The document is titled 'FORM DEFA14A' and references 'Schedule 14A' and 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934.' It is clearly identified as a 'Definitive Additional Materials' filing related to a proxy statement. The content includes a transcript of an interview with the CEO, which is provided as additional material to the proxy statement. The form DEFA14A is specifically used for filings related to executive compensation and proxy solicitation materials. Therefore, this document fits the category of Remuneration Information filings, which detail compensation for top executives and directors, often filed as DEF 14A or DEFA14A forms. The document is not an annual report, earnings release, or other financial report but rather proxy-related materials with remuneration focus.
2023-12-11 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.